Understanding Heart Problems from Chemotherapy in Children with Relapsed Leukemia
Official title: Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications
Funded at University of Pennsylvania · NIH-11129826 · Data updated 2026-11-12
This project aims to better understand how chemotherapy for relapsed acute myeloid leukemia (AML) affects the hearts of children and adolescents.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 15, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $329,736 |
| NIH project number | 5R01HL164925-04 |
| Project ID | NIH-11129826 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research focuses on children and adolescents, aged 0-11 years, who have experienced a relapse of acute myeloid leukemia and received intensive chemotherapy.
✕Less likely to help
Patients who have not been diagnosed with acute myeloid leukemia or who have not undergone chemotherapy for relapsed disease would not directly benefit from this specific research.
What this research studies
Children and adolescents with acute myeloid leukemia (AML) who experience a relapse face intensive chemotherapy, which can unfortunately lead to heart problems. We want to learn more about when these heart issues start, how they progress, and if children can recover from them. By looking at existing information from clinical trials and patient experiences, we hope to fill in the gaps in our current knowledge. This will help us understand the specific risks associated with different treatments for relapsed AML.
Why it matters
Potential benefit: If successful, this work could lead to better ways to monitor and protect the hearts of children undergoing chemotherapy for relapsed AML, potentially improving their long-term health.
How similar studies have gone: While the overall prognosis for pediatric AML has improved, there is a current lack of comprehensive data specifically on cardiotoxicity risks during and after treatment for relapsed disease.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Getz, Kelly Diringer — University of Pennsylvania
- Study coordinator: Getz, Kelly Diringer
Related research
Other NIH-funded projects on the same topics.
-
Cardiotoxicity in kids with relapsed AML and what it means for their hearts
A study tracking how chemotherapy for relapsed pediatric AML affects heart health over time and what that means for long-term wellbeing.
-
Investigating heart-related side effects in children with relapsed acute myeloid leukemia
This study is looking at how heart problems can affect kids who have had a relapse of acute myeloid leukemia after their chemotherapy, so we can better understand and manage these side effects during their treatment.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.